27480 Effect of apremilast on quality of life, pruritus, and psoriasis in special areas after 52 weeks of therapy in biologic-naive patients with moderate plaque psoriasis who did not achieve a PASI-75 response: Real-world, prospective study in Greece –APRAISAL

Background: Psoriasis therapeutic goals extend beyond Psoriasis Area and Severity Index (PASI) improvement to reducing psoriasis involvement in special areas and improving patients’ overall well-being. We present the effect of apremilast on the Dermatology Life Quality Index (DLQI), pruritus, and nail, scalp, and palmoplantar involvement in PASI-75 nonresponders.